Particle.news
Download on the App Store
5 ARTICLES
·
last mo.

Biohaven Investors Face Sept. 12 Deadline in Securities Class Action

The Connecticut case claims the company misled the market on the prospects of two key drug programs.

Bhvn deadline friday: rosen, a longstanding firm, encourages biohaven ltd. investors to secure counsel before important september 12 deadline in securities class action bhvn

Overview

  • Investors must file any motion to serve as lead plaintiff by September 12, 2025.
  • The lawsuit is filed in the U.S. District Court for the District of Connecticut and covers purchases from March 24, 2023 through May 14, 2025.
  • The complaint alleges Biohaven overstated troriluzole’s regulatory outlook and the sufficiency of data in its NDA for spinocerebellar ataxia.
  • It further alleges BHV-7000’s efficacy and clinical prospects for bipolar disorder were overstated, citing stock drops following disclosures on July 27, 2023, March 3, 2025, April 25, 2025, and May 14, 2025.
  • Multiple firms, including Rosen, Portnoy, The Gross Law Firm, and Bragar Eagel & Squire, are recruiting investors, and no class has been certified.